Benefitfocus Announces First Quarter 2017 Financial Results
Apr 27, 2017 20:07 pm UTC| Business
CHARLESTON, S.C., April 27, 2017 -- Benefitfocus, Inc. (NASDAQ:BNFT), a leading provider of cloud-based benefits management software, today announced its first quarter 2017 financial results. “Benefitfocus delivered a...
VASCO Reports Results for First Quarter 2017
Apr 27, 2017 20:07 pm UTC| Business
Q1 Total revenue of $42 millionQ1 GAAP operating income of $0.3 millionQ1 GAAP earnings per share of $0.01Q1 Non-GAAP earnings per share of $0.081 OAKBROOK TERRACE, Ill., and ZURICH, Switzerland, April 27, 2017 --...
VASCO Reports Results for First Quarter 2017
Apr 27, 2017 20:07 pm UTC| Business
Q1 Total revenue of $42 millionQ1 GAAP operating income of $0.3 millionQ1 GAAP earnings per share of $0.01Q1 Non-GAAP earnings per share of $0.081 OAKBROOK TERRACE, Ill., and ZURICH, Switzerland, April 27, 2017 --...
Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
Apr 27, 2017 20:07 pm UTC| Business
Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April 27, 2017 -- Alder BioPharmaceuticals, Inc....
VASCO Reports Results for First Quarter 2017
Apr 27, 2017 20:07 pm UTC| Business
Q1 Total revenue of $42 millionQ1 GAAP operating income of $0.3 millionQ1 GAAP earnings per share of $0.01Q1 Non-GAAP earnings per share of $0.081 OAKBROOK TERRACE, Ill., and ZURICH, Switzerland, April 27, 2017 --...
Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
Apr 27, 2017 20:07 pm UTC| Business
Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April 27, 2017 -- Alder BioPharmaceuticals, Inc....
Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results
Apr 27, 2017 20:07 pm UTC| Business
Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April 27, 2017 -- Alder BioPharmaceuticals, Inc....
Trump's Greenland Gambit Ignites Transatlantic Tariff War: Global Markets on Edge